patients with low probability of an acute coronary syndrome but not sufficiently low to allow discharge. CPUs are defined as organizational short stay units with specific management protocols designed to facilitate and optimize the diagnosis of patients with chest pain in whom the diagnosis has not yet been established and who are too high risk to be discharged immediately. The first chest pain centre was set up in 1981 in the United States (St. Agnes Hospital in Baltimore, Maryland, USA), and this concept has been tested in many observational and interventional trials. [7] [8] [9] In general, patients admitted to CPUs receive an accelerated diagnostic protocol consisting of serial ECGs and serial cardiac injury markers to exclude acute coronary syndrome. 1, 10, 11 Documented experience, mainly from the United States and the UK, has demonstrated that chest pain centres manage their patients as effectively as inpatient admission but in a shorter time and at lower cost. 7, 12 Recently, in Germany an almost complete network of 244 certified CPUs has been established. [13] [14] [15] [16] In Europe, many hospitals have developed elements of CPU care, however, often without establishing a formal CPU. 14 There is evidence that certified CPUs show better adherence to evidence-based acute coronary syndrome (ACS) guidelines than institutions without certified units. 17 More standardized installation and implementation of CPUs will enhance the quality of CPUs and improve the quality of care of our chest pain patients and even improve prognosis in patients with ACS. 18 Until now, no unified European criteria for the set up of CPUs have been defined. Therefore, a dedicated task force within the Acute Cardiovascular Care Association was established to develop an evidence-based framework for the development of CPUs. This task force represents a broad spectrum of clinicians with experience and expertise in the evaluation of chest pain patients presenting to EDs as well as the German CPU Group. This task force has elaborated and edited recommendations on organizational and logistic aspects of CPUs. These criteria regulate the physical and technical requirements and determine diagnostic and therapeutic strategies for patients with chest pain. As patient volume determines the size and organizational structure of a CPU, it was decided to establish a standard level describing the minimal criteria that all CPUs should fulfil and an advanced level for larger and more specialized CPUs.
Patient evaluation
Risk stratification of chest pain patients suspect for ACS begins with the initial clinical assessment, which provides information on the risk of cardiovascular complications and allows to select those patients most appropriate for the CPU (see Figure 1 ). Low ACS risk patients are those with no haemodynamic instability or severe arrhythmias and without objective evidence of ischaemia (a normal or near-normal ECG, with initial cardiac injury markers below the upper limit of normal). 9, 19, 20 Those patients can be admitted to the CPU for further evaluation by means of an accelerated diagnostic protocol consisting of serial ECGs and serial cardiac injury markers obtained over a 3-12 h period.
Recently, the HEART-score has proven to be an easy, quick and effective risk stratification tool in undifferentiated chest pain patients. 21, 22 Based on the patient's history, ECG, age, cardiovascular risk factors and cardiac troponin measurements, a score between 0 and 10 points is calculated, representing the patient's risk of developing a major adverse cardiac event within six weeks after initial presentation. This score is now being evaluated as a key decision-making tool for the initial evaluation of chest pain patients (CPU, coronary care unit (CCU), at home). 22, 23 It is essential that criteria for admission to the CPU from the ED are locally pre-defined by the cardiologists and the ED physicians.
Echocardiography may reveal regional wall motion abnormalities related to regional myocardial ischaemia. In addition, echocardiography is an important tool to establish a diagnosis of pericarditis, aorta dissection, or pulmonary embolism. Patients with negative findings usually complete the accelerated diagnostic protocol with an exercise or pharmacological stress test to exclude ischaemia.
A negative accelerated diagnostic evaluation allows early discharge, whereas patients with a positive test are admitted for further evaluation and treatment. In the case of the preferred strategy of pre-discharge testing being unavailable, outpatient stress testing can be proposed, particularly for very low-risk patients (patients with negative serial ECGs, negative cardiac injury markers, and no medical history of ischaemic heart disease). 
Organizational structure
CPUs occupy a designated area next to the ED. Alternatively, the CPU is part of the ED, primarily comprising personnel and process handling. Successful implementation of a CPU requires close coordination between emergency physicians and cardiologists.
A standard CPU should be supervised by a cardiologist, who can be in co-direction with an emergency physician, and should be equipped with a qualified doctor (or in training) for internal medicine/emergency medicine (see Table 1 ). The medical staff should be supported by at least one nurse per four beds, who is dedicated to CPU/emergency/CCU. A higher level of quality accreditation requires the permanent presence of a qualified specialist in cardiology or emergency medicine and the supervision of the department by a cardiologist. In addition, dedicated nurses qualified for CPU are required. 24 To ensure maximal benefits from the CPU concept, regular training (1/year) for all staff members is a prerequisite. Such training should include education and practical implementation of process of care for chest pain patients and should also encompass training in performing and interpreting diagnostic tests, such as ECG, biomarkers and non-invasive tests. Quality monitoring should be organized to measure and evaluate operational performance and adherence to evidence-based guidelines. Predefined quality measures can be extracted from hospital-based patient files. Participation in a specific CPU registry (local or supra-regional) with more continuous quality assessment is recommended for advanced level CPUs. A list of quality indicators for ACS patients has been recently published by the Acute Cardiovascular Care Association. 25 
Physical requirements (Table 2)
CPUs can be integrated into an ED with predefined continuous availability of 2-4 monitoring beds dedicated to chest pain patients. For more advanced CPU settings, a separate department adjacent to the ED is advisable. Such a department should contain at least four monitoring beds as well as a diagnostic/treatment room and a waiting room. Permanent access to heart catheterization and percutaneous coronary intervention (PCI) facilities should be possible. If a catheterization lab is not present at the hospital, predefined transfer protocols to a hospital with PCI facilities should be present and operational. This protocol includes the permanent availability of an intensive care mobile unit to transfer critically ill patients (cf. STEMI (ST segment elevation myocardial infarction), to a PCI hospital. (Table 3) ECG. Beyond the clinical status, the initial 12-lead ECG is the most informative tool for early risk stratification, and it should be obtained within 10 min of ED presentation. 26 The ECG provides important diagnostic and prognostic information and is pivotal in the triage process. Pre-hospital ECG is strongly recommended in patients attended by the emergency medical system as it allows an early triage of the patients. 27 If the initial ECG is negative, repeat ECGs are recommended to unravel evolving myocardial ischaemia or injury. An alternative and more sensitive method is continuous ST-segment monitoring using 12-lead monitoring. Its utility in indicating subclinical ischaemia has been demonstrated during observations of mainly high-risk patients presenting with chest pain, whereas its yield in low-risk patients is limited. 28, 29 For this reason, it is not obligatory in the standard CPU criteria.
Technical requirements
Additional ECG leads (posterior leads V7 to V9 and right-sided leads V3R to V4R) have been applied to increase the sensitivity of the ECG for the detection of myocardial ischaemia/injury. 30, 31 Heart rhythm and blood pressure monitoring. Myocardial ischaemia or injury may trigger life-threatening (e.g. ventricular tachycardia/fibrillation) or other arrhythmias (atrial fibrillation). For this reason, continuous rhythm monitoring, preferably centralized, is mandatory even in 'presumed' low-risk patients until the diagnosis of ACS is ruled out. A resuscitation set with a defibrillator must be available in the CPU. In addition, resuscitation and emergency plans should be in accordance with and integrated into hospital emergency protocols. Beyond tachy-arrhythmias, bradycardia due to atrio-ventricular block has been documented in patients with inferior ischaemia/injury and may require urgent pacing back-up. For this reason, a transcutaneous pacing modality should be available on the external defibrillator.
In addition to rhythm monitoring, blood pressure should be monitored for early detection of spontaneous or druginduced (e.g. nitrates) blood pressure drops and to evaluate drug-related control of hypertension. Preferably, this can be performed by automatic non-invasive blood pressure measurement at regular time intervals (e.g. every 15-30 min).
Cardiac biomarkers. Current guidelines recommend measurement of cardiac injury markers, which should include a highly sensitive and specific troponin assay for all patients with suspected myocardial ischaemia. 26 Cardiac troponins are more sensitive and specific markers of cardiomyocyte injury than creatine kinase (CK), its MB isoenzyme (CK-MB) and myoglobin. If the clinical presentation is compatible with myocardial ischaemia, then a dynamic elevation (rise and fall) of cardiac troponin above the 99th percentile of healthy individuals indicates myocardial infarction. 32 With the use of the highly sensitive troponin, serial troponin measurements at 3-h intervals (0 h/3 h algorithm) have been shown to accurately rule in or rule out myocardial infarction. 26, 33 This requires the presence of a 24-h emergency laboratory with turnaround time of <90 min (<60 min at advanced CPUs). If this cannot be achieved, point-of-care methods should be considered. However, the currently used point-of-care assays have lower diagnostic accuracy and are less thoroughly evaluated than the automated assays located in central laboratories. 34 With the development of more accurate troponin assays, shorter (0-1 h) rule in/rule out algorithms have been suggested. It should be stressed that for these shorter algorithms, the cut-off values are assayspecific and differ from the standard cut-off-values of 0 h/3 h algorithms. Those short algorithms should always be integrated with a detailed clinical assessment and 12-lead ECG, and repeat blood sampling is mandatory in the case of ongoing or recurrent chest pain. Those more recent techniques should be reserved for advanced level CPUs, but pending on growing expertise and on the development of more accurate assays, these short algorithms could be expanded to all CPUs in the future.
The utility of B-type natriuretic peptide has been demonstrated across a broad spectrum of ACS patients as a powerful prognostic risk indicator and as a marker of heart failure. However, its diagnostic value for detecting ischaemia is limited. 35 Beyond cardiac biomarkers, a general laboratory set containing electrolytes, renal and liver function, C-reactive protein and D-dimer should be available with turn-around times of <60 min.
Chest X-ray. Most patients with uncomplicated ACS have a normal chest X-ray. However, chest X-rays may reveal diagnostic clues for some other diseases related to the chest pain, such as aortic dissection, pericardial effusion, pleural effusion, pneumonia and pneumothorax. Hence, chest X-ray should be available preferably within 30 min.
Transthoracic echocardiography. Regional wall motion abnormalities (RWMAs) induced by ischaemia can be detected by rest echocardiography, but the extent of RWMA is highly dependent on the extent and duration of ischaemia/injury. 36, 37 Although normal rest echocardiography in chest pain patients is an indicator of low clinical risk, it may be insufficiently sensitive for the detection of subtle RWMAs that may reflect ischaemia in troponin-negative patients with unstable angina. 37 In addition, pre-existing wall motion abnormalities mitigate the diagnostic accuracy of detecting ischaemia. The diagnostic capability of echocardiography can be enhanced by the use of stress echocardiography (see below). In the absence of significant wall motion abnormalities, impaired myocardial perfusion detected by contrast echocardiography or reduced regional function using strain and strain rate imaging might improve the diagnostic and prognostic values of conventional echocardiography. 38, 39 Beyond evaluation of RWMA, transthoracic echocardiography is highly useful for detecting alternative pathologies associated with chest pain, such as pericardial effusion, ascending aortic syndromes, aortic valve stenosis, hypertrophic cardiomyopathy or right ventricular dilatation suggestive of acute pulmonary embolism.
Hence, this technique should be standard and available within 30 min. For advanced CPU settings, the permanent presence of ultrasound equipment is required.
Specific instrumental requirements.
Although pulse oxymetry is a standard test for each ED patient, more complete blood gas analysis might be highly useful in patients suspected of having a pulmonary embolism or suffering from hyperventilation. This test should be standard and available within 15 min. For advanced CPUs, a blood gas analysis machine should be integrated into the CPU department.
In some patients with respiratory insufficiency in the setting of an ACS, non-invasive ventilation may be required and should be available within 30 min. The permanent presence of non-invasive ventilation equipment is recommended for advanced CPUs.
In the case of the patient needing to be transported for additional examinations (e.g. catheterization lab), transport monitoring/ventilating systems should be available within 30 min. Those transport systems should be permanently present in the advanced CPU setting.
Management (Table 4)
Clinical risk scores. A useful approach to risk stratification has been the development of risk scores. Besides the Heartscore (see section Patient evaluation), The Global Registry of Acute Coronary Events (GRACE) scoring system has been reported to accurately predict risk in patients presenting with acute coronary syndromes. 40 Favourable (low risk) scores allow consideration for CPU management. Whereas the GRACE score provides information on ischaemic risk, specific risk scores have been developed to assess bleeding risk. The Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) bleeding risk score was developed from a cohort of non-ST segment elevation acute coronary syndrome (NSTE-ACS) patients undergoing invasive evaluation to estimate the patient's likelihood of an in-hospital major bleeding event. 41, 42 In patients being medically treated or on oral anticoagulants, the predictive value of these scores is not established.
Ischaemic and bleeding risks need to be weighed in the individual patient, although many of the predictors of ischaemic events are also associated with bleeding complications.
Non-invasive testing. In low-risk patients with normal baseline ECG and able to exercise, exercise ECG testing is frequently used as part of the CPU diagnostic protocol. The validity and safety of symptom-limited exercise ECG within 12 h after negative observation has been documented by multiple studies. 29, 43 To optimize the safety, the stopping rules are stricter, for example, stop at onset of minimal criteria for ischaemia (0.1 mV of ST segment shift). Exercise ECG testing is, however, hampered by suboptimal sensitivity (68%) and specificity (77%) at detecting coronary artery disease and requires a (near) normal baseline ECG and maximal exercise (85% of age-predicted maximum heart rate). 44 The rationale of performing this easily-available test in the CPU setting is to risk stratify patients to a very low probability of ACS if the exercise ECG test is negative and to allow early discharge with eventual out-patient cardiac re-evaluation. 43 Stress imaging, either pharmacologically-or exerciseinduced, is more sensitive and specific than ECG stress testing and is recommended in recent guidelines due to its greater diagnostic accuracy. 44 Echocardiography reveals stress-induced wall motion abnormalities whereas scintigraphy evaluates stress-induced perfusion defects. Resting myocardial scintigraphy, by detecting fixed perfusion defects suggestive of myocardial necrosis, can also be helpful for initial triage of patients presenting with chest pain without ECG changes or without elevated cardiac troponins. 45 Multidetector computed tomography (MDCT) allows visualization of the coronary arteries. Recent studies have reported overall high negative predictive values for excluding ACS (by excluding coronary artery disease (CAD)) and excellent outcomes in patients presenting to the ED with low to intermediate pre-test probability for ACS and a normal coronary computed tomography (CT) angiogram. 26, 46, 47 Patients with high probability of CAD are not good candidates as MDCT does not allow an accurate assessment of stenosis severity. In addition, CT imaging can effectively exclude other causes of acute chest pain, such as pulmonary embolism, aortic dissection, pneumonia and tension pneumothorax. 48 Cardiac magnetic resonance (CMR) can assess both perfusion and wall motion abnormalities, and patients presenting with acute chest pain with a normal stress CMR have an excellent short-and midterm prognosis. CMR also permits detection of scar tissue (using late gadolinium enhancement) and oedema and may facilitate the differential diagnosis between infarction and myocarditis or Takotsubo cardiomyopathy. 49 All of these imaging tests require more expertise and equipment than the standard exercise ECG and are also less likely to be available as a 24 h service.
When pre-discharge stress testing is unavailable, outpatient testing can be performed shortly after discharge in a selected group of patients. Those patients should be without further discomfort and with negative serial troponin and should receive an appointment schedule at the time of discharge.
Treatment. Patients with chest pain of unknown origin should be treated initially only with aspirin (or clopidogrel if contraindicated).
Once a specific diagnosis has been obtained, treatment should follow recommendations by the specific guidelines for the different diseases (STEMI, NSTE-ACS, unstable angina, pericarditis, acute pulmonary embolism, aortic dissection, hypertensive crisis, arrhythmias, cardiogenic shock, pneumonia, pneumothorax).
For STEMI patients, an urgent invasive evaluation is recommended with a target door-in-door-out time < 30 min if the patient needs to be transferred to a PCI centre and with a target door-to-balloon time of < 60 min if a catheterization lab is present on site. 25, 50 For NSTE-ACS patients, an invasive evaluation should be performed within 24 h for high-risk patients and within 72 h for moderate-risk patients. 26 A discharge policy from the CPU to home or a hospital ward should be available.
Conclusion
CPUs are facilities with specific management protocols designed to facilitate and optimize: the diagnosis of patients consulting with chest pain in the ED. The present document is intended to standardize and facilitate the installation of a CPU nearby to the ED or as an integral part of the ED to improve the quality of care of our chest pain patients. In the future, these criteria can be applied in the certification process of CPUs both at a standard and an advanced level.
